BACKGROUND: This secondary analysis examined the impact of methadone initiated in prison on postrelease HIV risk behaviors. The parent study was a three-group randomized clinical trial in which participants received drug abuse counseling in prison and were randomly assigned to: (1) passive referral to substance abuse treatment upon release; (2) guaranteed methadone treatment admission upon release; and (3) methadone in prison and guaranteed continuation of methadone upon release. METHODS:Participants were 211 adult males with preincarceration histories of opiate dependence. The AIDS Risk Assessment was administered at baseline (in prison) and at 1-, 3-, 6-, and 12-month postrelease. Data were analyzed for the entire sample (N = 211) as well as the subsamples who reported injecting drugs in the 30 days prior to incarceration (n = 131) and who reported having unprotected sex in that time frame (n = 144) using generalized linear mixed model on an intent-to-treat basis. RESULTS: There were no significant changes in sex- or drug-risk by Condition over Time. There were significant Time and Condition main effects for the total sample as well as the injector subsample for drug-risk behaviors. There were no significant Condition main effects for HIV sex-risk behaviors, but there were significant Time main effects. CONCLUSIONS:Methadone initiated in prison or immediately postrelease is associated with reduced HIV drug-risk compared to counseling in prison without methadone and passive referral to treatment at release. Participation in several drug- and sex-risk behaviors also showed significant declines during the postrelease time periods.
RCT Entities:
BACKGROUND: This secondary analysis examined the impact of methadone initiated in prison on postrelease HIV risk behaviors. The parent study was a three-group randomized clinical trial in which participants received drug abuse counseling in prison and were randomly assigned to: (1) passive referral to substance abuse treatment upon release; (2) guaranteed methadone treatment admission upon release; and (3) methadone in prison and guaranteed continuation of methadone upon release. METHODS:Participants were 211 adult males with preincarceration histories of opiate dependence. The AIDS Risk Assessment was administered at baseline (in prison) and at 1-, 3-, 6-, and 12-month postrelease. Data were analyzed for the entire sample (N = 211) as well as the subsamples who reported injecting drugs in the 30 days prior to incarceration (n = 131) and who reported having unprotected sex in that time frame (n = 144) using generalized linear mixed model on an intent-to-treat basis. RESULTS: There were no significant changes in sex- or drug-risk by Condition over Time. There were significant Time and Condition main effects for the total sample as well as the injector subsample for drug-risk behaviors. There were no significant Condition main effects for HIV sex-risk behaviors, but there were significant Time main effects. CONCLUSIONS:Methadone initiated in prison or immediately postrelease is associated with reduced HIV drug-risk compared to counseling in prison without methadone and passive referral to treatment at release. Participation in several drug- and sex-risk behaviors also showed significant declines during the postrelease time periods.
Authors: Linda R Gowing; Michael Farrell; Reinhard Bornemann; Lynn E Sullivan; Robert L Ali Journal: J Gen Intern Med Date: 2005-12-07 Impact factor: 5.128
Authors: Stephen Magura; Joshua D Lee; Jason Hershberger; Herman Joseph; Lisa Marsch; Carol Shropshire; Andrew Rosenblum Journal: Drug Alcohol Depend Date: 2008-10-18 Impact factor: 4.492
Authors: M-J S Milloy; Jane Buxton; Evan Wood; Kathy Li; Julio S G Montaner; Thomas Kerr Journal: BMC Public Health Date: 2009-05-27 Impact factor: 3.295
Authors: Olga Morozova; Lyuba Azbel; Yevgeny Grishaev; Sergii Dvoryak; Jeffrey A Wickersham; Frederick L Altice Journal: Int J Prison Health Date: 2013
Authors: Alexander R Bazazi; Jeffrey A Wickersham; Martin P Wegman; Gabriel J Culbert; Veena Pillai; Roman Shrestha; Haider Al-Darraji; Michael M Copenhaver; Adeeba Kamarulzaman; Frederick L Altice Journal: Contemp Clin Trials Date: 2017-05-04 Impact factor: 2.226
Authors: Fiona G Kouyoumdjian; Kathryn E McIsaac; Jessica Liauw; Samantha Green; Fareen Karachiwalla; Winnie Siu; Kaite Burkholder; Ingrid Binswanger; Lori Kiefer; Stuart A Kinner; Mo Korchinski; Flora I Matheson; Pam Young; Stephen W Hwang Journal: Am J Public Health Date: 2015-02-25 Impact factor: 9.308
Authors: Nina T Harawa; Russell Brewer; Victoria Buckman; Santhoshini Ramani; Aditya Khanna; Kayo Fujimoto; John A Schneider Journal: Am J Public Health Date: 2018-11 Impact factor: 9.308